Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Dow
Moodys
Argus Health
Johnson and Johnson
US Army
US Department of Justice
Daiichi Sankyo
Queensland Health

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021093

« Back to Dashboard

NDA 021093 describes ATACAND HCT, which is a drug marketed by Astrazeneca and is included in one NDA. It is available from three suppliers. Additional details are available on the ATACAND HCT profile page.

The generic ingredient in ATACAND HCT is candesartan cilexetil; hydrochlorothiazide. There are twenty-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the candesartan cilexetil; hydrochlorothiazide profile page.
Summary for 021093
Tradename:ATACAND HCT
Applicant:Astrazeneca
Ingredient:candesartan cilexetil; hydrochlorothiazide
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021093
Ingredient-typeThiazides
Mechanism of ActionAngiotensin 2 Receptor Antagonists
Physiological EffectIncreased Diuresis
Suppliers and Packaging for NDA: 021093
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093 NDA AstraZeneca Pharmaceuticals LP 0186-0162 N 0186-0162-54
ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093 NDA AstraZeneca Pharmaceuticals LP 0186-0322 N 0186-0322-54

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength16MG;12.5MG
Approval Date:Sep 5, 2000TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength32MG;12.5MG
Approval Date:Sep 5, 2000TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength32MG;25MG
Approval Date:May 16, 2008TE:ABRLD:Yes

Expired US Patents for NDA 021093

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-002 Sep 5, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-003 May 16, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-001 Sep 5, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-001 Sep 5, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-002 Sep 5, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-003 May 16, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-002 Sep 5, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-001 Sep 5, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-001 Sep 5, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-002 Sep 5, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Cantor Fitzgerald
Argus Health
Fish and Richardson
QuintilesIMS
Cerilliant
Dow
Cipla
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot